Table 3. Rates of SVR for patients with decompensated cirrhosis HCV genotype 1 (phase III/IV studies).

Regimen	Duration	Patients	SVR rate	Study (reference)
LDV – SOF ± RBV	12 – 24 weeks	Naïve and TE	86–89%	SOLAR-1 82
LDV – SOF ± RBV	12 – 24 weeks	Naïve and TE	84–92%	SOLAR-2 95
SOF + RBV SIM – SOF SIM – SOF + RBV	12 weeks 12 weeks 12 weeks	Naïve and TE Naïve and TE Naïve and TE	52% 74% 66%	HCV-Target 96
DCV – SOF + RBV	12 weeks	Naïve and TE	56–94% *	ALLY-1 97
LDV – SOF LDV – SOF + RBV DCV – SOF DCV – SOF + RBV	12 weeks 12 weeks 12 weeks 12 weeks	Naïve and TE Naïve and TE Naïve and TE Naïve and TE	81% 86% 60% # 82%	UK cohort EAP 81
SIM – SOF ± RBV	12 weeks	Naïve and TE	69–79%	Saxena et al. 46
SIM – SOF ± RBV	12 weeks	Naïve and TE	68%	Aqel et al. 89
SIM – SOF	12 weeks	Naïve and TE	67–77%	Shiffman et al. 90
SIM – SOF SIM – SOF + RBV	12 weeks 12 weeks	Naïve and TE Naïve and TE	52–65% 44–65% #	Backus et al. 98
SOF – VPV SOF – VPV + RBV SOF – VPV	12 weeks 12 weeks 24 weeks	Naïve and TE	88% 96% 92%	ASTRAL-4 99

a. Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; VPV, velpatasvir

b. ^*Also included patients with HCV genotype 2, 3, and 4

c. ^#Fewer than 10 patients were included in a specific subgroup